EUVIMEDEUVIMED entdecken
Open Access

Ultra-Hypofractionated Palliative Radiotherapy for Symptomatic Locoregionally Advanced Breast Cancer: A Prospective, Single-Arm Phase II Trial of Toxicity and Quality-of-Life Outcomes

Haresh Kunhi Parambath, Subhash Gupta, Arun Thimmarayappa, Yousra Izzuddeen Kn, Anjali V Ramdulari

Breast Care · 23.06.2026 · 1-10

DOI: 10.1159/000552778 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Care, online erschienen am 23.06.2026. Verfasst von Haresh Kunhi Parambath und 4 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aim of the study was to report the safety, efficacy, and patient-reported outcomes of a prospective trial of weekly hypofractionated radiotherapy (RT) for symptomatic locoregionally advanced breast cancer.

Methods

In this single-arm, prospective phase II trial, 24 patients received a palliative RT course of 40 Gy delivered in five, weekly 8-Gy fractions. The primary endpoint was dose-limiting toxicity (DLT), defined as grade ≥3 acute radiation dermatitis. Secondary endpoints included objective response rate (ORR) and health-related quality of life (HRQoL), assessed longitudinally using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30/BR23 and Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaires.

Results

All 24 enrolled patients completed the prescribed treatment. The regimen led to profound and statistically significant improvements in EORTC Global Health/QoL scores (+44.1 points; 95% Confidence Intetval [CI]: 34.6 to 53.7; p < 0.001) and pain scores (−33.3; 95% CI: −39.0 to −27.7; p < 0.001) at 3 months, which were sustained at 6 months. At 3 months, the Overall Response Rate (ORR) was 40.9% (95% CI: 20.7% to 63.6%). The primary DLT was grade ≥3 acute dermatitis, occurring in 29.2% of patients; however, this toxicity was transient, with all events occurring at treatment completion and the rate decreasing to 8.3% by the 1-month follow-up.

Conclusion

This signal-seeking study demonstrates the feasibility of a 40 Gy in 5-fraction palliative regimen. It presents a manageable, transient acute toxicity profile and offers promising signals of symptom palliation, locoregional disease control, and associated improvements in patient-reported QoL.

Schlagwörter

Stichwörter der Autor:innen

HypofractionationLocally advanced breast cancerPatient-reported outcomeQuality of life

Autor:innen und Institutionen

  • Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.
  • Neurosurgery, National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Radiation Oncology, Burjeel Medical City, Abu Dhabi, UAE.

Zitieren

APA

Parambath, H. K., Gupta, S., Thimmarayappa, A., Kn, Y. I., & Ramdulari, A. V. (2026). Ultra-Hypofractionated Palliative Radiotherapy for Symptomatic Locoregionally Advanced Breast Cancer: A Prospective, Single-Arm Phase II Trial of Toxicity and Quality-of-Life Outcomes. Breast Care, 1-10. https://doi.org/10.1159/000552778

Vancouver

Parambath HK, Gupta S, Thimmarayappa A, Kn YI, Ramdulari AV. Ultra-Hypofractionated Palliative Radiotherapy for Symptomatic Locoregionally Advanced Breast Cancer: A Prospective, Single-Arm Phase II Trial of Toxicity and Quality-of-Life Outcomes. Breast Care. 2026:1-10. doi:10.1159/000552778

BibTeX
@article{Parambath2026,
  author = {Parambath, Haresh Kunhi and Gupta, Subhash and Thimmarayappa, Arun and Kn, Yousra Izzuddeen and Ramdulari, Anjali V},
  title = {Ultra-Hypofractionated Palliative Radiotherapy for Symptomatic Locoregionally Advanced Breast Cancer: A Prospective, Single-Arm Phase II Trial of Toxicity and Quality-of-Life Outcomes},
  journal = {Breast Care},
  year = {2026},
  pages = {1--10},
  doi = {10.1159/000552778}
}
Kostenlos starten →